HMR, Pfizer, G.D. Searle regulatory update

The FDA's Cardiovascular and Renal Drugs Advisory Committee recommended that the label for short-acting nifedipine, a calcium channel blocker for the treatment of angina, be modified to include advice against its use in hypertension, unstable angina and acute myocardial infarction. ...